# Needle free diabetes care Market

> Needle Free Diabetes Care Market Research Report, By Devices Types (Treatment Devices And Diagnostic Devices), Treatment (Oral Insulin, Inhaled Insulin, Insulin Patch, Others), Application (Insulin Delivery And Other), End Users (Diagnostic Centers, Hospitals & Clinics And Other) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.74%
- **2024:** $ 13.12 Billion
- **2025:** $ 14.14 Billion
- **2035:** $ 29.79 Billion
- **Key Players:** Insulet Corporation (US), Medtronic (US), Novo Nordisk (DK), Becton Dickinson and Company (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), Roche (CH), Abbott Laboratories (US)

**Report ID:** MRFR/MED/0407-HCR · **Pages:** 110 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/needle-free-diabetes-care-market-912

---

## Market Summary

## **Needle-Free Diabetes Care Market Overview**

Needle Free Diabetes Care Market Size was valued at USD 12.45 Billion in 2023. The Global Needle Free Diabetes Care industry is projected to grow from USD 13.12 Billion in 2024 to USD 23.20 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.69% during the forecast period (2024 - 2032). This is because of the growing diabetes population across the globe. People are looking for needle-free options for the intake of insulin.

Diabetes may be termed as a group of metabolic disorders, caused due to insulin deficiency. Needle-free medication is growing popular because it is a modern option to administer pain-free insulin medication to the patient. The diabetic population is multiplying around the world, which is expected to drive the needle-free diabetes care market growth.

Moreover, a large share of the population is also suffering from obesity. This has led to a rise in healthcare expenditure. The government is also rendering strong support for medication facilities, which will contribute to the growth of the market. Studies show that smoking adds to the probability of having diabetes in people. Moreover, more than 60% of the global population comprises smokers. This fact is also known to increase the risk of diabetes and may fuel the growth of the needle-free healthcare market.

**Covid-19 Analysis**

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The needle-less diabetes healthcare market saw a slight downfall post the pandemic, due to the lockdown and physical distancing.

However, the key companies have adopted measures to sell needle-free diabetes medication online. Moreover, people are growing aware of the need for needle-less diabetes healthcare provisions. Hence, these factors are expected to boost the growth of the needle-free diabetes care market value in the years to come.

Gennova Biopharmaceuticals, one of PharmaJet’s partners, submitted the data for its needle-free mRNA-based booster shot Omicron-specific Covid-19 for EUA to the Drug Controller General of India (DCGI) in April 2023.

NuGen Medical Devices published a study on InsuJet™, its needle-free injection device, in March 2023, stating that it yielded over 40% faster insulin uptake and significantly quicker onset of action on diabetic patients versus multiple clinical trials carried out across the Netherlands using needles.PharmaJet was also selected by WHO for million+ polio vaccination campaigns in Pakistan in August 2022. In this endeavor, the company will administer needle-free vaccines to 2.7 million children.NovaXS Biotech from the United States unveiled a new prototype of its smart medical device for needle-free injection therapy also in June 2022.

The company’s patent-pending technology, Telosis propels a tiny stream of medicine within just 0.3 seconds without puncturing a needle while evaluating the coming injections data so that more informed decisions about the patient can be made by doctors. As the first remote medication and self-administration monitoring platform, the firm suggested that it provided an easy and painless option to deliver drugs at home. NovaXS’ first indication is IVF procedures.Gerresheimer AG and Portal Instruments have joined forces to bring innovative needle-free drug delivery solutions to chronically ill patients, as announced in May 2022.

Their aim is to make injections painless for patients together.NovaXS Biotech has recently secured investment support for their patented needle-free injector early this year – March 2022.

This device is connected via cloud with doctors who have access to information about their patients based on how much time they are being injected, how often they receive shots, how much volume should be administered at each dose, as well as what temperature medication should be maintained before taking effect.Take, for example, Gerresheimer AG, in May 2022, increased its range of drug delivery technologies with an investment in Portal Instruments based in the United States, which is a developer of the next-generation needle-free drug delivery technology.

Gerresheimer and Portal Instruments have teamed up to improve the patient experience, especially for patients suffering chronic illnesses such as those requiring injectable biologics and biosimilars. These advances into new technological areas and collaboration between market players are poised to stimulate market growth.

## **Needle-Free Diabetes Care Market Trends**

### **Drivers**

A few factors may drive the growth of the needle-free diabetes care market share. There have been increasing cases of diabetes and obesity in the population around the globe. These cases have contributed to the hike in healthcare expenditure for the people. Moreover, the government has been rendering strong support to the development of needle-free medication for diabetes. Hence, these factors are expected to accelerate global market growth.

### **Opportunities**

The major companies that account for the largest needle-free diabetes care market share are adopting various trends such as new product launches in the field. The advancements in technology and research are adding to its growth. Moreover, most companies are adopting R&D market trends. Hence, these factors serve as opportunities for global market growth.

### **Restraints**

There are a few factors that may inhibit the growth of the needle-free diabetes care market. One of the most important of them is the lack of awareness among people regarding the use of needle-free healthcare. Moreover, these needle-less diabetes care products are a bit expensive. Hence, these factors may hinder market growth.

### **Challenges**

Some factors that may challenge the key diabetes healthcare providers include the cost of needle-free products. They are quite expensive and are not affordable to the majority of the diabetic population around the globe. These needle-free care products are also not available that easily. Hence, these factors challenge the key companies of the global market.

### **Cumulative Growth Analysis**

The needle-free diabetes care market is anticipated to grow at a high speed in the years to come. This is because of the growing diabetes population across the globe. People are looking for needle-free options for the intake of insulin.

### **Value Chain Analysis**

People are growing aware of needle-free diabetes healthcare products. These products are growing popular because of the numerous benefits they offer, without having to hurt your skin or body. Many key companies of the market have also adopted trends such as innovations and product launches. The government is also supporting market research and development. Hence, these factors may fuel the growth of the industry in the global needle-free diabetes care market forecast.

## **Needle-Free Diabetes Care Market Segmentation**

The global needle-free diabetes care market is classified into many segments such as device types, treatment, application, and end-user. Listed below are the needle-less diabetes healthcare market segments:

### **Needle-Free Diabetes Care Market By Device Types**

### **Needle-Free Diabetes Care Market By Treatment**

### **Needle-Free Diabetes Care Market By Application**

### **Needle-Free Diabetes Care Market By End-user**

### **Needle-Free Diabetes Care Market Regional Analysis**

The regional division of the needle-free diabetes care market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. Among them, North America is expected to rule over the global market over the forecast period (2022 – 2030). This is because most of the obese and diabetic population in the globe belongs to the North American region.

Moreover, there are huge changes in the lifestyle of people to maintain their health. This region will be followed by Europe, with the second-largest share in the global needle-free diabetes care industry. However, the Asia Pacific region is anticipated to witness the fastest market growth rate over the forecast period. This is because the Asia Pacific comprises a large share of the diabetic population.

## **Competitive Landscape**

The needle-free diabetes care industry is dominated by a few companies that play a vital role in the growth of the market. These healthcare companies are called the key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various needle-free diabetes care market trends such as joint ventures, product launches, company expansions, and procurements. They are innovative insulin medication options for diabetic patients.

### **Key Players**

Below are the key companies that offer needle-free diabetes care in the global market, with the location of their headquarters:

### **Recent Developments **

### **Report Overview**

This report delivers all the information about the growth of the global needle-free diabetes care market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected needle-free diabetes care market outlook by the year 2030.

### **Geographically**

## Market Drivers

### Rising Prevalence of Diabetes

The Needle Free Diabetes Care Market is significantly influenced by the rising prevalence of diabetes worldwide. As the number of individuals diagnosed with diabetes continues to increase, the demand for effective and less invasive treatment options is also on the rise. Current statistics indicate that approximately 463 million adults are living with diabetes, a figure that is expected to reach 700 million by 2045. This alarming trend underscores the urgent need for innovative solutions, such as needle-free delivery systems, which can facilitate better management of the condition. The growing awareness of diabetes complications further propels the market, as patients seek alternatives that minimize discomfort while ensuring effective treatment.

### Patient-Centric Healthcare Trends

The Needle Free Diabetes Care Market is benefiting from a shift towards patient-centric healthcare models. This trend emphasizes the importance of patient comfort and satisfaction in treatment protocols. As healthcare providers increasingly prioritize the patient experience, needle-free options are becoming more attractive. The convenience of these systems, which often allow for self-administration, aligns with the growing demand for personalized healthcare solutions. Furthermore, studies suggest that patient compliance improves when treatment methods are less invasive. This shift not only enhances the quality of care but also drives market growth, as more patients opt for needle-free alternatives that align with their lifestyle and preferences.

### Government Initiatives and Funding

The Needle Free Diabetes Care Market is also being propelled by various government initiatives aimed at improving diabetes care. Many governments are investing in research and development to promote innovative healthcare solutions, including needle-free delivery systems. Funding programs and grants are increasingly available to support the development of technologies that enhance patient care. For instance, initiatives aimed at reducing healthcare costs and improving patient outcomes are likely to encourage the adoption of needle-free options. This supportive regulatory environment not only fosters innovation but also creates a favorable market landscape for companies specializing in needle-free diabetes care solutions.

### Integration of Wearable Technology

The Needle Free Diabetes Care Market is poised for growth due to the integration of wearable technology in diabetes management. Wearable devices that monitor glucose levels continuously are becoming increasingly popular, allowing for real-time data collection and analysis. This integration facilitates the development of needle-free delivery systems that can be synchronized with these devices, providing a seamless experience for users. The market for wearable technology in diabetes care is expected to reach USD 27 billion by 2026, indicating a robust demand for innovative solutions. As patients seek more efficient ways to manage their condition, the combination of wearables and needle-free systems presents a compelling opportunity for market expansion.

### Technological Innovations in Needle-Free Devices

The Needle Free Diabetes Care Market is experiencing a surge in technological innovations that enhance the efficacy and user-friendliness of diabetes management devices. Recent advancements in microneedle technology and jet injectors have made it possible to deliver insulin and other medications without the discomfort associated with traditional needles. These innovations not only improve patient experience but also increase adherence to treatment regimens. According to recent estimates, the market for needle-free delivery systems is projected to grow at a compound annual growth rate of approximately 8% over the next five years. This growth is indicative of a broader trend towards minimizing pain and anxiety associated with diabetes care, thereby making needle-free options more appealing to patients.

## Future Outlook

The Needle-Free Diabetes Care Market is projected to grow at a 7.74% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for patient-friendly solutions.

**New opportunities:**

- Development of smart needle-free devices with integrated data analytics Expansion into emerging markets with tailored product offerings Partnerships with healthcare providers for integrated diabetes management solutions

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in diabetes care innovation.

## Segment Insights

### By Device Types: Continuous Glucose Monitoring (Largest) vs. Insulin Pen (Fastest-Growing)

The Needle-Free Diabetes Care Market is predominantly segmented into various device types, with Continuous Glucose Monitoring (CGM) leading the charge as the market's largest segment. Diagnostic devices and instant glucose monitoring play crucial roles in patient management, contributing significantly to overall market dynamics. Additionally, treatment devices such as insulin pens and patches are also noteworthy, as they address different patient needs and preferences, further diversifying the market landscape.

Continuous Glucose Monitoring (Dominant) vs. Insulin Pen (Emerging)

Continuous Glucose Monitoring (CGM) systems are at the forefront of diabetes management, providing real-time glucose levels and historical trends to users. These devices enhance patient autonomy and facilitate timely interventions, making them highly appealing in the market. Conversely, insulin pens have emerged as an increasingly popular choice for treatment, especially among individuals seeking ease of use and discreet delivery methods. As new technologies evolve, such as [smart insulin pens](https://www.marketresearchfuture.com/reports/smart-insulin-pens-market-6789) with connectivity features, their adoption rates are likely to rise, indicating their status as an emerging category within the market.

### By Treatment: Insulin Patch (Largest) vs. Inhaled Insulin (Fastest-Growing)

The Needle-Free Diabetes Care Market comprises several key treatment options, namely insulin patches, inhaled insulin, oral insulin, and other methods. Among these, insulin patches currently hold the largest market share due to their convenience, ease of use, and non-invasive nature. Inhaled insulin, on the other hand, is gaining rapid popularity, attracting attention for its potential to revolutionize insulin delivery by providing faster absorption compared to traditional methods. Oral insulin and other methods follow, marking notable efforts to enhance patient adherence and optimize diabetes management.

Insulin Patch (Dominant) vs. Inhaled Insulin (Emerging)

The insulin patch has established itself as a dominant force within the Needle-Free Diabetes Care Market, primarily due to its user-friendly application and consistent dosage delivery, making it appealing to a broad range of diabetic patients. This segment is characterized by advancements in technology that enhance skin adhesion and drug stability, contributing to user satisfaction. On the contrary, inhaled insulin is regarded as an emerging solution, emphasizing speed and convenience. It targets patients who may have difficulties with traditional injections or whose lifestyle demands a more adaptable insulin delivery option. As clinical trials yield encouraging results, inhaled insulin is positioned to expand significantly, striking a balance between efficacy and patient preference.

### By Application: Insulin Delivery (Largest) vs. Others (Fastest-Growing)

The Needle-Free Diabetes Care Market is primarily dominated by the Insulin Delivery segment, which has established itself as the largest category due to the increasing prevalence of diabetes and the rising demand for less invasive treatment alternatives. This segment captures a significant share of the overall market, as patients increasingly prefer needle-free systems that offer convenience and pain reduction during insulin administration. In contrast, the 'Others' segment, which includes various alternative applications and delivery methods, is rapidly gaining traction as innovative solutions emerge, catering to a broader range of diabetes care options.

Insulin Delivery (Dominant) vs. Others (Emerging)

The Insulin Delivery segment stands out as the dominant player within the Needle-Free Diabetes Care Market, as it focuses on providing efficient and user-friendly solutions for insulin administration without needles. This category addresses critical patient needs by minimizing pain and anxiety associated with traditional injection methods. The emergence of advanced technologies in insulin delivery systems has significantly contributed to its strong market position. Conversely, the 'Others' segment is recognized as an emerging category that encompasses a diverse range of newer technologies aimed at enhancing diabetes management, such as smart pens and integrated delivery systems. The evolving landscape of diabetes care is fueling growth in this segment as more patients look for innovative solutions that enhance their treatment experiences.

### By End-user: Hospitals & Clinics (Largest) vs. Diagnostic Centres (Fastest-Growing)

In the Needle-Free Diabetes Care Market, the end-user segment is distributed primarily among hospitals & clinics, diagnostic centres, and other healthcare providers. Currently, hospitals and clinics hold the largest share due to their extensive patient base and continuous demand for efficient diabetes management solutions. This dominance is reinforced by their ability to invest in advanced technology and treatment methods, fulfilling the needs of diabetic patients effectively. Meanwhile, diagnostic centres are increasingly capturing market attention, driven by rising awareness and demand for non-invasive diabetes screening methods.

Hospitals & Clinics (Dominant) vs. Diagnostic Centres (Emerging)

The hospitals & clinics segment is characterized by a significant volume of diabetes management procedures, making it the dominant end-user in the Needle-Free Diabetes Care Market. These facilities benefit from strong patient inflow and a diverse range of medical services, including preventive care and chronic disease management. Additionally, the integration of needle-free devices enhances patient comfort and compliance, further solidifying their position in the market. On the other hand, diagnostic centres represent an emerging segment focusing on innovative testing methods. As awareness surrounding diabetes increases, these centres are leveraging advanced technologies to provide rapid and pain-free testing solutions, thereby attracting a growing clientele who prefer convenience without compromising accuracy.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for needle-free diabetes care, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high diabetes prevalence, and increasing demand for non-invasive treatment options. Regulatory support from agencies like the FDA has accelerated the approval of innovative devices, driving market growth. The rising awareness of diabetes management and technological advancements further fuel demand. The United States is the primary contributor, with key players like Insulet Corporation, Medtronic, and Abbott Laboratories leading the market. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. Canada also plays a significant role, focusing on improving diabetes care through needle-free technologies, enhancing patient compliance and comfort.

### Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the needle-free diabetes care market, accounting for approximately 30% of the global share. The region's growth is driven by increasing diabetes prevalence, supportive healthcare policies, and a strong emphasis on patient-centric care. Countries like Germany and France are leading the charge, with regulatory bodies promoting innovative healthcare solutions to improve patient outcomes. The European Medicines Agency (EMA) has been instrumental in facilitating the approval of new technologies. Germany stands out as a key market, with major players like Novo Nordisk and Sanofi actively investing in needle-free solutions. The competitive landscape is marked by collaborations between pharmaceutical companies and technology firms, enhancing product offerings. The focus on reducing the burden of diabetes management is driving demand for needle-free devices, making Europe a vital region for market expansion.

### Asia-Pacific : Rapid Growth in Emerging Economies

Asia-Pacific is rapidly emerging as a significant player in the needle-free diabetes care market, holding about 20% of the global share. The region's growth is fueled by rising diabetes rates, increasing healthcare expenditure, and a growing awareness of non-invasive treatment options. Countries like China and India are at the forefront, with government initiatives aimed at improving diabetes management and healthcare access. Regulatory frameworks are evolving to support innovative [medical devices](https://www.marketresearchfuture.com/reports/medical-devices-market-2869), further driving market growth. China is the largest market in the region, with a strong presence of local and international players. Companies like Becton Dickinson and Medtronic are expanding their operations to cater to the growing demand. The competitive landscape is characterized by a mix of established firms and emerging startups, focusing on technological advancements and affordability to enhance patient compliance and care.

### Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region is gradually recognizing the potential of needle-free diabetes care, currently holding about 5% of the global market share. The growth is driven by increasing diabetes prevalence, rising healthcare investments, and a shift towards innovative treatment solutions. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at improving healthcare infrastructure and access to diabetes care. Regulatory bodies are beginning to support the introduction of advanced medical technologies. South Africa is a key market, with a growing number of healthcare providers adopting needle-free solutions to enhance patient comfort. The competitive landscape is still developing, with both local and international players exploring opportunities in this emerging market. The focus on improving diabetes management and patient outcomes is expected to drive future growth in the region.

## Competitive Benchmarking

The Needle-Free Diabetes Care Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for patient-friendly solutions. Key players such as Insulet Corporation (US), Medtronic (US), and Novo Nordisk (DK) are at the forefront, each adopting distinct strategies to enhance their market positioning. Insulet Corporation (US) focuses on innovation through its Omnipod system, which offers a tubeless insulin delivery solution, while Medtronic (US) emphasizes digital transformation with its integrated diabetes management systems. Novo Nordisk (DK), on the other hand, is leveraging partnerships to expand its product offerings and reach, particularly in emerging markets. Collectively, these strategies contribute to a competitive environment that is increasingly centered around patient-centric solutions and technological integration.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and operational excellence. This competitive structure allows for a diverse range of products and services, catering to varying patient needs and preferences.

In August 2025, Insulet Corporation (US) announced a strategic partnership with a leading technology firm to enhance its data analytics capabilities. This collaboration aims to improve patient outcomes by providing real-time insights into insulin delivery and glucose monitoring. The strategic importance of this move lies in its potential to position Insulet as a leader in personalized diabetes management, leveraging data to drive better health outcomes.

In September 2025, Medtronic (US) launched a new version of its insulin pump that integrates advanced AI algorithms for predictive analytics. This innovation is expected to significantly improve the user experience by anticipating insulin needs based on real-time data. The introduction of AI into diabetes care reflects a broader trend towards digitalization, indicating Medtronic's commitment to staying ahead in a competitive market.

In July 2025, Novo Nordisk (DK) expanded its product line by introducing a needle-free delivery system for its GLP-1 receptor agonists. This strategic move not only enhances patient compliance but also aligns with the growing demand for less invasive treatment options. By diversifying its offerings, Novo Nordisk is likely to strengthen its market position and appeal to a broader patient demographic.

As of October 2025, current competitive trends in the Needle-Free Diabetes Care Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing unique, patient-centric solutions that not only meet regulatory standards but also enhance the overall patient experience.

## Recent News & Developments

Echo Therapeutics has developed a needle-free diabetic tester that uses a patch instead of a needle poke. The transdermal biosensor examines the blood analytes through the skin with blood drawn from the body.

DiaMonTech launched its diabetes monitor D-Base that measures blood glucose levels by passing an infrared ray through the skin. The levels are evaluated by monitoring the temperature changes on the skin.

Portal Instruments launched its jet-injection device that injects insulin into the skin through a ‘hair-thin’ stream.

## Report Scope

| MARKET SIZE 2024 | 13.12(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 14.14(USD Billion) |
| MARKET SIZE 2035 | 29.79(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.74% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Insulet Corporation (US), Medtronic (US), Novo Nordisk (DK), Becton Dickinson and Company (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), Roche (CH), Abbott Laboratories (US) |
| Segments Covered | Devices Types |
| Key Market Opportunities | Advancements in technology enable innovative solutions for pain-free glucose monitoring in the Needle-Free Diabetes Care Market. |
| Key Market Dynamics | Technological advancements drive adoption of needle-free devices, enhancing patient compliance and reshaping diabetes management strategies. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Needle-Free Diabetes Care Market by 2035?**
A: The projected market valuation for the Needle-Free Diabetes Care Market is expected to reach 29.79 USD Billion by 2035.

**Q: What was the market valuation of the Needle-Free Diabetes Care Market in 2024?**
A: The overall market valuation was 13.12 USD Billion in 2024.

**Q: What is the expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035 is 7.74%.

**Q: Which companies are considered key players in the Needle-Free Diabetes Care Market?**
A: Key players in the Needle-Free Diabetes Care Market include Insulet Corporation, Medtronic, Novo Nordisk, and others.

**Q: What are the projected values for Continuous Glucose Monitoring devices by 2035?**
A: The projected value for Continuous Glucose Monitoring devices is expected to reach 7.0 USD Billion by 2035.

**Q: How much is the Insulin Patch segment expected to grow by 2035?**
A: The Insulin Patch segment is projected to grow to 5.5 USD Billion by 2035.

**Q: What is the expected market size for Insulin Delivery applications by 2035?**
A: The expected market size for Insulin Delivery applications is anticipated to reach 18.0 USD Billion by 2035.

**Q: What is the projected market size for hospitals and clinics as end-users by 2035?**
A: The projected market size for hospitals and clinics as end-users is expected to reach 12.0 USD Billion by 2035.

**Q: What is the expected growth for Instant Glucose Monitoring devices by 2035?**
A: The expected growth for Instant Glucose Monitoring devices is projected to reach 4.5 USD Billion by 2035.

**Q: What are the anticipated values for the Others segment in the Treatment category by 2035?**
A: The anticipated value for the Others segment in the Treatment category is expected to reach 13.79 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/needle-free-diabetes-care-market-912*